Arca biopharma provides update on aspen-covid-19 phase 2b clinical trial evaluating rnapc2 as a potential treatment for covid-19

Westminster, colo., july 13, 2021 (globe newswire) -- arca biopharma, inc. (nasdaq: abio), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today provided an update on aspen-covid-19, the phase 2b clinical trial evaluating rnapc2 as a potential treatment for patients hospitalized with covid-19.
ABIO Ratings Summary
ABIO Quant Ranking